5-Amino-1MQ: The NNMT Inhibitor Is Not a Peptide

Almost everything sold alongside it in this catalogue is a peptide — a chain of amino acids joined by amide bonds. 5-Amino-1MQ is not. It is 5-amino-1-methylquinolinium, a small permanently charged heterocycle, and the difference is not pedantry. It changes what the molecule does, how it reaches its target, and how it should be handled on the bench.

In short

5-Amino-1MQ is a membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using SAM as the methyl donor. Inhibiting it spares nicotinamide for NAD+ salvage and spares the methyl group. In diet-induced obese mice, a methylquinolinium NNMT inhibitor reduced body weight, white adipose mass and adipocyte size without changing food intake.

5-Amino-1MQ is a small molecule, not a peptide

The quinolinium core is a fused bicyclic aromatic with a methylated ring nitrogen. That methylation leaves the nitrogen quaternary, so the molecule carries a permanent positive charge rather than the pH-dependent charge a peptide carries. There is no amide backbone, no sequence, and nothing for a protease to cut.

Practically, the failure modes you learn with peptides do not transfer. It will not aggregate the way a hydrophobic peptide does, it does not care about aminopeptidases, and molecular-weight arithmetic behaves normally because there is no salt-form or net-peptide-content correction to apply.

5-amino-1mq vial from Soraci Labs
5-Amino-1MQ is a quinolinium small molecule, not a peptide chain.

What NNMT actually does

NNMT catalyses one reaction: it takes nicotinamide and transfers a methyl group to it from S-adenosylmethionine, producing 1-methylnicotinamide and S-adenosylhomocysteine. One substrate, one cofactor, two products. The enzyme sits predominantly in adipose tissue and liver.

That single reaction sits at the junction of two separate budgets, which is why an enzyme this simple attracts so much attention.

Why methylating nicotinamide costs twice

The first cost is NAD+. In mammals the salvage pathway accounts for more than 85% of NAD+ synthesis, and nicotinamide is its substrate. Every nicotinamide molecule NNMT methylates is one that cannot be recycled back into NAD+. The enzyme is, in effect, a drain on the main NAD+ supply line.

The second cost is the methyl group itself. SAM is the cell’s universal methyl donor, used for DNA and histone methylation among much else, and NNMT consumes it stoichiometrically while generating SAH. A tissue running NNMT hard is spending methyl currency and producing the product that inhibits other methyltransferases.

  • Substrate: nicotinamide — the NAD+ salvage input
  • Cofactor: S-adenosylmethionine — the universal methyl donor
  • Products: 1-methylnicotinamide and S-adenosylhomocysteine
  • Highest expression: adipose tissue and liver

What the 5-amino-1mq animal data measured

The study usually cited is Neelakantan and colleagues, Biochemical Pharmacology 2018. They gave diet-induced obese mice a potent methylquinolinium-class NNMT inhibitor and reported reduced body weight, reduced white adipose mass, smaller adipocytes and lower plasma total cholesterol.

The detail that makes the result interesting is the control: food intake did not change. Weight loss without appetite suppression points at the metabolic mechanism rather than at eating behaviour. Intracellular 1-methylnicotinamide fell while NAD+ and SAM rose, which is exactly what inhibiting the enzyme should do.

What it is not: a human trial. This is a mouse obesity model, and the distance between a rodent adipose phenotype and anything else is the part most summaries skip.

Where 5-amino-1mq sits among NNMT inhibitors

Inhibitors of this enzyme fall into three broad classes. Nicotinamide-competitive compounds occupy the substrate site — 5-Amino-1MQ belongs here, as does 1-methylnicotinamide itself. SAM-competitive compounds such as sinefungin block the cofactor site. Dual-substrate inhibitors are designed to bridge both.

Substrate-competitive inhibition is a meaningful design choice: the cofactor site is shared across the methyltransferase family, so blocking it tends to be less selective. The nicotinamide pocket is the more specific address.

Handling: not a peptide, not stored like one

Because it is a small charged heterocycle rather than a protein, the usual peptide anxieties — freeze-thaw damage, surface adsorption, aggregation — are much less relevant. It is still sensible to keep the sealed vial cold and dark, and to protect solutions from light.

The arithmetic is also simpler. With a peptide you have to know the salt form and the net peptide content before a milligram figure means anything. A defined small molecule has a single molecular weight and a stated purity, so mass to moles is a one-step calculation.

Frequently asked questions

Is 5-amino-1mq a peptide?
No. It is 5-amino-1-methylquinolinium, a small permanently charged aromatic heterocycle. It has no amide backbone and no amino-acid sequence, so peptide-specific handling and molecular-weight corrections do not apply.
What enzyme does it inhibit?
Nicotinamide N-methyltransferase (NNMT), which methylates nicotinamide using SAM, producing 1-methylnicotinamide and SAH. NNMT is expressed most heavily in adipose tissue and liver.
How does NNMT relate to NAD+?
Nicotinamide is the substrate of the NAD+ salvage pathway, which supplies more than 85% of mammalian NAD+. Methylating nicotinamide removes it from that pathway, so NNMT activity competes directly with NAD+ regeneration.
What did the mouse study actually show?
In diet-induced obese mice, a methylquinolinium NNMT inhibitor reduced body weight, white adipose mass and adipocyte size, and lowered plasma total cholesterol, with no change in food intake (Neelakantan et al., Biochemical Pharmacology, 2018).
Is there human evidence?
The frequently cited efficacy data are from rodent models. Treat the animal findings as animal findings.

References

The primary literature below is indexed on PubMed, and compound records are held at PubChem.

  • Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology 2018;147:141–152. PubMed 29155147
  • Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Frontiers in Pharmacology 2024. Full text

All Soraci Labs products are sold for laboratory research use only. They are not drugs, supplements or cosmetics, and are not for human or veterinary use, diagnosis or treatment. Nothing on this page is guidance for use in people.

One comment

Leave a Reply

Your email address will not be published. Required fields are marked *